JAFRON
30052918.600.38% ( +0.07 )
JAFRON (300529)
Jafron Biomedical Co.,Ltd. engages in the research, development, production, and sale of blood purification products for hemadsorption field worldwide. The comp...
- Open
- 18.30
- High
- 18.66
- Low
- 18.10
- Prev. Close
- 18.53
- Volume
- 76.23K
- Turnover
- 140.68M
- Avg Price
- 18.45
- Bid/Ask Ratio
- --
- Amplitude
- 3.02%
- 52wk High
- 24.16
- Volume Ratio
- 0.62
- Turnover Ratio
- 0.95%
JAFRON Analyst Rating
View MoreForecast & Rating
Jun 9, 2026Price forecast
¥24.1129.65%
Forecast & RatingStrong buy
2analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Zhitong · Oct 29, 2025 at 11:11 AM
JAFRON released its performance for the first three quarters, with a net profit attributable to the parent company of 453 million yuan, a decrease of 42.75%
- Zhitong · Jun 18, 2025 at 05:20 AM
JAFRON: The extracorporeal circulation blood pathway of the blood purification device has obtained EU MDR certification
- Zhitong · Apr 15, 2025 at 08:04 AM
JAFRON released its first-quarter performance, with a net profit attributable to the parent company of 189 million yuan, a year-on-year decrease of 33.71%
- Zhitong · Apr 15, 2025 at 07:52 AM
JAFRON released its 2024 annual performance, with a net profit attributable to shareholders of 820 million yuan, a year-on-year increase of 87.91%
- Simplywall · Mar 16, 2025 at 10:16 PM
Jafron Biomedical Co.,Ltd. (SZSE:300529) insiders have significant skin in the game with 51% ownership
- Zhitong · Mar 14, 2025 at 03:32 AM
JAFRON products have obtained EU MDR certification
